EZH2 accompanies prostate cancer progression
Author:
- 6 September 2021
- journal article
- editorial
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (9) , 934-936
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription ActivatorCell Reports, 2018
- Patient derived organoids to model rare prostate cancer phenotypesNature Communications, 2018
- Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic FunctionMolecular Cell, 2018
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistanceScience, 2017
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerCancer Cell, 2016
- Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomasEpigenetics, 2016
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-IndependentScience, 2012
- Cooperation between Polycomb and androgen receptor during oncogenic transformationGenome Research, 2011
- Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2Nature Cell Biology, 2010
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002